SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Anjali S AdvaniAnna B MoseleyKristen M O'DwyerBrent L WoodMin FangMatthew J WieduwiltIbrahim AldossJae H ParkRebecca B KlisovicMaria R BaerWendy StockRupali R BhaveMegan K D OthusRichard C HarveyCheryl L WillmanMark R LitzowRichard M StoneElad SharonHarry P ErbaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome-negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.